Phase 1 Clinical Trial Of PV-10 In Recurrent Breast Cancer Complete, Says Provectus Pharmaceuticals
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. Craig Dees, CEO of Provectus, noted, “We are very pleased with the results of this Phase 1 clinical trial, a classic ascending dose study. Its goals were to determine the safety of the treatment and the appropriate dosage.
More: continued here
Filed under: Breast Cancer on October 29th, 2008